Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Contraception
Interventions: Eutectic Lidocaine Prilocaine, Subcutaneous Lidocaine; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, EBV Positive Plasma Cell Neoplasm
Interventions: Injection of EBV Specific CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Shoulder Arthroplasty
Interventions: ReUnion TSA System; Device
Lead sponsor: Stryker Trauma and Extremities; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Peoria, Illinois • Nashville, Michigan • Greenville, South Carolina

Conditions: Shigellosis
Interventions: Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 8 Months to 50 Years
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 0
States / cities: Not listed

Conditions: Stress
Interventions: Corporate Athlete® Resilience; Behavioral
Lead sponsor: Johnson & Johnson Health and Wellness Solutions, Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Metabolism
Interventions: Water-soluble choline, Fat-soluble choline, No choline control; Other
Lead sponsor: Utah State University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Metastatic Colorectal Cancer
Interventions: αDC1 vaccine, CKM; Biological · Drug
Lead sponsor: Pawel Kalinski; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product; Drug
Lead sponsor: Amneal Ireland Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Brookhaven, New York

Conditions: Obesity
Interventions: Weight loss counseling, Portion-Controlled Foods; Behavioral · Dietary Supplement
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Parkinson Disease
Interventions: Sham Manipulation; Other
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 50 Years and older
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Sarcoma
Interventions: sirolimus; Drug
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Discussion, Exercise Intervention, Informational Intervention, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Medication Adherence
Interventions: Adherence Counseling, General Health Counseling, Text Messages; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Non Small Cell Lung Cancer Stage
Interventions: Hypo-Fractionation, Standard-Fractionation; Radiation
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Kansas City, Kansas • Overland Park, Kansas • Topeka, Kansas + 3 more

Conditions: Acute Respiratory Failure
Interventions: Ketamine, Sedative drug regimen; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Spondyloarthropathies
Interventions: CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 32
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Paul Richardson, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more

Conditions: Vaccination
Interventions: Control Site, Intervention Site, Patient-level Control Group, Patient-level Intervention Group; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 23
States / cities: Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 12 more

Conditions: Celiac Disease
Interventions: KAN-101, Placebo; Drug
Lead sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 13
States / cities: Anaheim, California • Walnut Creek, California • Aventura, Florida + 10 more

Conditions: Inflammation
Interventions: Morphine Sulfate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Neuroblastoma
Interventions: Ceritinib, dasatinib, sorafenib, vorinostat, DFMO; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: Up to 22 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2035
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more

Conditions: Multiple Sclerosis
Interventions: Narrow pulse, Wide pulse; Device
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Depression
Interventions: Infliximab, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Migraine
Interventions: Nasal Carbon Dioxide, Placebo; Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland • Portsmouth, Virginia

Search by objective public record fields.

Nexplanon Removal: Subcutaneous vs. Topical Lidocaine

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

A Post-Market Clinical Evaluation of the ReUnion TSA System

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

A Mixed Methods Evaluation of HPI Resilience Intervention Study

Choline Source, Gut Microbiota and Trimethylamine-N-oxide Response

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

A Randomized Trial Comparing Two Doses of Portion-Controlled Foods Within a Primary Care Weight Loss Program

Effects of OMT on Gait Kinematics and Postural Control in Parkinson Disease

Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer

Nurse Delivered Cell Phone Adherence Intervention (Pick It UP)

Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Pharmacokinetic Alterations During ECMO

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

P3+ Intervention Phase

Assessment of KAN-101 in Celiac Disease (ACeD)

Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis

Inflammation-Induced CNS Glutamate Changes in Depression

The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine